Cypris Therapeutics, a NYC-based drug discovery company, raised over $500K in Pre-Seed funding.
The round was led by Ichor Life Sciences, a Syracuse-based contract research organization. Cypris will incubate at Ichor’s facilities and gain access to Ichor’s equipment in addition to drug discovery and development expertise.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Kyle Parella, Cypris Therapeutics keverages proprietary technology that enables the synthesis and iteration of complex small molecule moieties that have been previously unattainable by researchers. The molecules are inspired by those found in nature with demonstrated therapeutic properties. It can modify these natural molecules to improve their therapeutic properties and reduce undesired side effects. This synthetic chemistry innovation holds the potential to improve the standard of care for patients that do not respond to existing treatments.
FinSMEs
25/06/2024